Goldman Sachs is out with a research note this morning, where it suggests that traders buy calendar spreads on Aruba Networks UTHR ahead of upcoming positive Phase 3 data.
Goldman Sachs Biotechnology analyst, Terence Flynn, rates UTHR shares Buy and sees 19% upside to his 12-month price target of $82. He rates UTHR a M&A probability of 1 (strong, 30% - 50% probability in one year) once results from Phase 3 data on their upcoming Pulmonary Arterial Hypertension (PAH) are released this year.
Goldman suggests buying the August $75.00 call and selling the January 2012 $90.00 call for a net debit of $1.45
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the medical needs of patients with chronic diseases.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date of Trade | ticker | Put/Call | Strike Price | DTE | Sentiment |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.